Please assess the completion status of the following clinical trial:

Trial Title: A Trial of Tadalafil in Patients With Squamous Cell Carcinoma of the Upper Aero Digestive Tract

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Histologically confirmed, previously untreated invasive head and neck squamous cell carcinoma OR histologically confirmed not yet treated recurrent head and neck squamous cell carcinoma (must be at least 3 months after diagnosis and completion of treatment for primary disease or last recurrence).~2. Disease location amenable to biopsy in outpatient clinical setting or operative biopsy within routine accepted schedule and practice of clinical care~3. No medical contraindication to biopsy of target lesion.~4. ECOG performance status 0-1~5. Required laboratory data (to be obtained within 4 weeks of initiation):~   * Platelets \> 75,000/mm³~  * Calculated Creatinine Clearance (CRCL)\> 60 mL/min iii. Total serum bilirubin \< 1.5 mg/dL.~  * No intercurrent illness likely to prevent protocol therapy or surgical resection~6. Patients with a history of a curatively treated malignancy must be disease-free and have a survival prognosis that exceeds five years.~7. Female patients must not be pregnant or breast feeding. A negative pregnancy test is required within 14 days of randomization for all women of childbearing potential.~8. Willingness and ability to give signed written informed consent.~Exclusion Criteria:~1. Known severe hypersensitivity to tadalafil or any of the excipients of this product~2. Patients who have a concurrent malignancy or a history of previous malignancy treated with curative therapy within the last 3 months (other than squamous/basal cell cancer of the skin or cervical cancer) who have a survival prognosis of \< 5 years.~3. Treatment with a non-approved or investigational drug within 30 days before day 1 of trial treatment.~4. Incomplete healing from previous oncologic or other major surgery.~5. Pregnancy or breast feeding (women of childbearing potential).~6. As judged by the investigator, any evidence of severe or uncontrolled systemic disease (e.g., unstable or uncompensated respiratory, cardiac, hepatic, or renal disease).~7. Evidence of any other significant clinical disorder or laboratory finding that makes it undesirable for the subject to participate in the trial.~8. Current therapy with ketoconazole or oral antifungal therapy.~9. History of significant hypotensive episode requiring hospitalization.~10. A history of acute myocardial infarction within prior 3 months, uncontrolled angina,~11. Uncontrolled arrhythmia, or uncontrolled congestive heart failure~12. Age \< 18~13. History of any of the following cardiac conditions:~    * Angina requiring treatment with long-acting nitrates.~   * Angina requiring treatment with short-acting nitrates within 90 days of planned tadalafil administration.~   * Unstable angina within 90 days of visit 1 (Braunwald 1989).~   * Positive cardiac stress test without documented evidence of subsequent, effective cardiac intervention.~14. History of any of the following coronary conditions within 90 days of planned tadalafil administration:~    * Myocardial Infarction.~   * Coronary artery bypass graft surgery.~   * Percutaneous coronary intervention (for example, angioplasty or stent placement).~   * Any evidence of heart disease (NYHA≥Class III as defined in Protocol Attachment LVHG.3) within 6 months of planned tadalafil administration~15. Current treatment with nitrates.~16. Current systemic treatment with a potent cytochrome P450 3A4 (CYP3A4) inhibitor such as ketoconazole or ritonavir.~17. Received treatment within the last 30 days with a drug or device that has not received regulatory approval for any indication at the time of Visit 1.~18. Prior chronic immune suppressive state (AIDS, immunosuppressive therapy).~19. History of hypotension and/or blindness during prior treatment with Tadalafil or other PDE-5 inhibitors.~20. prior history of non-arterial ischemic optic retinopathy

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 99 Years
- Healthy Volunteers: f

Study Arms:
- Placebo (Type: PLACEBO_COMPARATOR): None
- Tadalafil (Type: EXPERIMENTAL): Tadalafil 20 mg once per day

Based on this trial design, predict the completion outcome and termination type (if applicable).